STOCK TITAN

SeaStar Medical Holding Corporation (ICU) Stock News

ICU NASDAQ

SeaStar Medical Holding Corporation develops and commercializes extracorporeal medical-device therapies for critically ill patients with organ failure driven by hyperinflammation. Its first commercial product, QUELIMMUNE (SCD-PED), is based on the company’s Selective Cytopheretic Device technology and is FDA approved for pediatric acute kidney injury associated with sepsis or a septic condition in patients requiring renal replacement therapy.

Recurring company updates cover QUELIMMUNE adoption by children’s hospitals, SAVE post-approval registry data, publications and conference presentations, and financial results. News also addresses clinical development of SCD therapy in adult acute kidney injury requiring continuous renal replacement therapy and in cardio-renal indications, as well as FDA Breakthrough Device and Humanitarian Device pathways for additional SCD uses.

Rhea-AI Summary

SeaStar Medical (Nasdaq: ICU) reported third-quarter 2026 net revenue of $635 thousand as sales of its QUELIMMUNE pediatric therapy increased. Revenue rose 247% year over year, with gross profit margins above 90%. Net loss widened to $4.529 million from $3.472 million, while loss per share narrowed to $1.03 from $1.30.

Cash was $3.989 million at September 30, excluding $3.3 million in gross proceeds from October warrant exercises. The adult NEUTRALIZE-AKI trial enrolled 251 of 339 patients; the company expects enrollment completion by mid-year 2027. The first module of its FDA approval application was submitted. Pediatric SAVE Registry results showed statistically significant higher survival versus comparator cohorts, with no device-related adverse events. FDA post-approval registry requirements were fulfilled, allowing hospitals to use QUELIMMUNE without the registry’s research infrastructure.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-45.31%
Tags
-
Rhea-AI Summary

SeaStar Medical (Nasdaq: ICU) will report its third quarter financial results after market close on November 11, 2026. A webcast and conference call to discuss the results and business progress will begin at 4:30 p.m. ET / 2:30 p.m. MT. A replay will be available after 7:30 p.m. ET.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.00%
Tags
earnings date
-
Rhea-AI Summary

SeaStar Medical (ICU) announced that the FDA determined QUELIMMUNE’s SAVE Registry fulfilled the therapy’s post-approval study requirements for pediatric patients. The requirements were part of the original Humanitarian Device Exemption approval. Hospitals can now use the therapy without the registry’s research infrastructure, enabling access at centers previously unable to participate for children with sepsis-associated acute kidney injury requiring renal replacement therapy.

Registry results presented at ASN Kidney Week 2026 showed 90-day survival of 65.1% in QUELIMMUNE patients (N=43), versus 47.5% in clinically aligned Kids’ Inpatient Database cohorts (N=196; P=0.043). In-hospital and 60-day survival also improved statistically significantly in the primary analysis. No device-related adverse events were reported in registry patients. SeaStar plans to continue voluntary registry enrollment at participating centers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.68%
Tags
none
Rhea-AI Summary

SeaStar Medical (ICU) reported statistically significant higher survival with QUELIMMUNE in a post-approval analysis of children with sepsis-associated acute kidney injury.

The observational study compared treated patients with historical hospital database cohorts requiring continuous kidney replacement therapy. In the primary analysis, Day 90 survival was 65.1% versus 47.4% (P=0.043), with 43 treated patients and 196 comparators. Survival to hospital discharge was also higher (P=0.04). A landmark sensitivity analysis found Day 90 survival of 63.8% versus 48.7%, but did not reach statistical significance (P=0.074).

No device-related adverse events occurred among treated SAVE registry patients. At Day 90, 20 of 24 survivors not requiring kidney replacement therapy at baseline were independent of it. The company expects final results and interpretations in a peer-reviewed manuscript.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.09%
Tags
none
-
Rhea-AI Summary

SeaStar Medical (ICU) announced that Chief Medical Officer Kevin Chung, MD, has been named the 2026 Combat Nephrology Award recipient.

The award recognizes contributions to kidney support in trauma, combat casualty and other high-acuity settings, linking military medicine with civilian critical care. Chung will accept the award at the Update in Critical Care Nephrology meeting in Madrid, Spain, held October 14–15, 2026. He is also the conference keynote speaker, presenting AKI in Military Operations: From Battlefield Experience to Future Strategies on October 15 at 8:00 a.m. GMT.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.16%
Tags
none
-
Rhea-AI Summary

SeaStar Medical (Nasdaq: ICU) received FDA Breakthrough Device Designation for SCD therapy targeting hyperinflammation in adults with sepsis or a septic condition. The Selective Cytopheretic Device, or SCD, now has seven Breakthrough Device Designations across different indications. The designation provides a pathway that can accelerate development, assessment and review for FDA approval; it is not an approval.

The ongoing NEUTRALIZE-AKI pivotal clinical trial includes a pre-specified statistical analysis of patients with sepsis or a septic-like condition. SeaStar expects data for this indication in the near term and plans to submit relevant data to the FDA as quickly as possible. Earlier designations cover inflammatory conditions involving acute kidney injury, adult and pediatric cardiac surgery, heart failure with worsening kidney function, chronic dialysis and hepatorenal syndrome.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.61%
Tags
none
Rhea-AI Summary

SeaStar Medical (Nasdaq: ICU) entered warrant-exercise agreements on October 2, 2026, expected to generate approximately $3.3 million in gross proceeds. The agreements cover immediate exercise of outstanding warrants for up to 854,002 common shares at a reduced price of $3.866 per share, versus original exercise prices of $6.38 to $7.62.

In exchange for cash exercise, SeaStar Medical will issue new warrants to purchase up to 1,708,004 common shares at $3.616 per share. These warrants are immediately exercisable and divided into two equal tranches with different expiration periods. Closing is expected on or about October 5, 2026, subject to customary closing conditions. Gross proceeds exclude placement agent fees and other offering expenses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.31%
Tags
-
Rhea-AI Summary

SeaStar Medical (ICU) announced acceptance of a late-breaking abstract for presentation at ASN Kidney Week on October 22, 2026.

The abstract evaluates post-approval SAVE Registry data, comparing the pediatric Selective Cytopheretic Device surveillance registry with a historical cohort in pediatric sepsis-associated acute kidney injury. Poster TH-PO1291 will be presented from 10:00 a.m. to 12:00 p.m. MT in Exhibit Hall A at the Colorado Convention Center in Denver. The meeting runs October 21–25, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.07%
Tags
none
-
Rhea-AI Summary

SeaStar Medical (ICU) announced new hospital procedure codes for its SCD therapy, effective October 1, 2026, for acute kidney injury.

The three ICD-10-PCS codes, used to report inpatient procedures, cover patients requiring renal replacement therapy, which replaces kidney filtration. They distinguish intermittent, prolonged intermittent and continuous urinary filtration using selective cytopheresis. Hospitals can use them for billing, documentation and statistical reporting. SeaStar Medical expects simpler coding to broaden access to QUELIMMUNE for children and support adoption of SCD therapy for adults with acute kidney injury, if approved.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.82%
Tags
none
Rhea-AI Summary

SeaStar Medical (ICU) Chief Medical Officer Kevin Chung will present at the PPETS conference in Houston on October 6, 2026.

His talk will use QUELIMMUNE to discuss the development of a therapy for critically ill children with acute kidney injury. James Odum will give a separate presentation on SeaStar Medical’s Selective Cytopheretic Device therapy during the same session.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
none

FAQ

What is the current stock price of SeaStar Medical Holding (ICU)?

SeaStar Medical Holding (ICU) last closed at $1.04.

What is the market cap of SeaStar Medical Holding (ICU)?

The market cap of SeaStar Medical Holding (ICU) is approximately $5.5M.